0001140361-17-010973.txt : 20170308 0001140361-17-010973.hdr.sgml : 20170308 20170308115130 ACCESSION NUMBER: 0001140361-17-010973 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170306 FILED AS OF DATE: 20170308 DATE AS OF CHANGE: 20170308 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEVRO CORP CENTRAL INDEX KEY: 0001444380 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 562568057 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1800 BRIDGE PARKWAY CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-251-0005 MAIL ADDRESS: STREET 1: 1800 BRIDGE PARKWAY CITY: REDWOOD CITY STATE: CA ZIP: 94065 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Enxing Michael CENTRAL INDEX KEY: 0001622421 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36715 FILM NUMBER: 17674341 MAIL ADDRESS: STREET 1: C/O NEVRO CORP. STREET 2: 4040 CAMPBELL AVE. CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 doc1.xml FORM 4 X0306 4 2017-03-06 0 0001444380 NEVRO CORP NVRO 0001622421 Enxing Michael C/O NEVRO CORP. 1800 BRIDGE PARKWAY REDWOOD CITY CA 94065 0 1 0 0 VP of Sales Common Stock 2017-03-06 4 S 0 37000 90.989 D 40463 D Common Stock 2017-03-06 4 M 0 1500 3.60 A 41963 D Common Stock 2017-03-06 4 S 0 800 90.9038 D 41163 D Common Stock 2017-03-06 4 S 0 600 92.3533 D 40563 D Common Stock 2017-03-06 4 S 0 100 92.85 D 40463 D Stock Option (Right to Buy) 3.60 2017-03-06 4 M 0 1500 0.00 D 2022-12-17 Common Stock 1500 38608 D The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Includes 2,500 restricted stock units. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $90.80 to $91.13, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $91.81 to $92.71, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. 100% of the shares subject to the option are fully vested and exercisable. /s/ Andrew Galligan, as Attorney-in-Fact for Michael Enxing 2017-03-08